Strs Ohio cut its position in Immunomedics, Inc. (NASDAQ:IMMU) by 4.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 73,351 shares of the biopharmaceutical company’s stock after selling 3,300 shares during the quarter. Strs Ohio’s holdings in Immunomedics were worth $1,409,000 at the end of the most recent quarter.
Several other hedge funds also recently added to or reduced their stakes in IMMU. BlackRock Inc. lifted its stake in Immunomedics by 3.6% in the fourth quarter. BlackRock Inc. now owns 12,639,350 shares of the biopharmaceutical company’s stock valued at $180,363,000 after acquiring an additional 435,568 shares during the last quarter. FMR LLC lifted its stake in shares of Immunomedics by 48.2% in the fourth quarter. FMR LLC now owns 8,235,480 shares of the biopharmaceutical company’s stock worth $117,519,000 after buying an additional 2,677,246 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Immunomedics by 45.2% in the fourth quarter. American Century Companies Inc. now owns 3,116,769 shares of the biopharmaceutical company’s stock worth $44,476,000 after buying an additional 970,128 shares during the last quarter. Foresite Capital Management III LLC lifted its stake in shares of Immunomedics by 0.3% in the fourth quarter. Foresite Capital Management III LLC now owns 2,700,000 shares of the biopharmaceutical company’s stock worth $38,529,000 after buying an additional 8,271 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in shares of Immunomedics by 14.3% in the fourth quarter. Jennison Associates LLC now owns 2,471,401 shares of the biopharmaceutical company’s stock worth $35,267,000 after buying an additional 309,886 shares during the last quarter. Institutional investors own 86.11% of the company’s stock.
In other news, Director Avoro Capital Advisors Llc purchased 500,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were acquired at an average cost of $15.07 per share, for a total transaction of $7,535,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 14.80% of the company’s stock.
Immunomedics stock traded down $1.03 during trading hours on Wednesday, reaching $14.80. 1,679,100 shares of the company’s stock traded hands, compared to its average volume of 3,056,925. The company has a current ratio of 7.89, a quick ratio of 7.89 and a debt-to-equity ratio of 0.04. Immunomedics, Inc. has a fifty-two week low of $11.55 and a fifty-two week high of $27.33. The company has a market cap of $3.03 billion, a PE ratio of -14.37 and a beta of 1.97.
Immunomedics (NASDAQ:IMMU) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). During the same quarter in the prior year, the business posted ($0.21) EPS. Research analysts forecast that Immunomedics, Inc. will post -1.63 EPS for the current year.
Several equities research analysts have issued reports on IMMU shares. ValuEngine raised shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 14th. Piper Jaffray Companies lowered their price target on shares of Immunomedics to $20.00 and set an “overweight” rating on the stock in a report on Tuesday, January 22nd. Berenberg Bank started coverage on shares of Immunomedics in a report on Wednesday, March 27th. They issued a “buy” rating and a $40.00 target price on the stock. BidaskClub lowered shares of Immunomedics from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Finally, HC Wainwright assumed coverage on shares of Immunomedics in a report on Monday, March 4th. They issued a “buy” rating and a $28.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. Immunomedics has an average rating of “Buy” and a consensus price target of $28.45.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Sundance Herald and is owned by of Sundance Herald. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://sundanceherald.com/2019/05/22/immunomedics-inc-immu-shares-sold-by-strs-ohio.html.
Immunomedics Company Profile
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.
Read More: What is Elliott Wave theory?
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.